InstalabLoading...
InstalabLoading...
If your kidneys, lungs, sinuses, or skin start showing unexplained inflammation, your immune system may be attacking your own blood vessels. PR3 (proteinase 3) antibody is one of the most specific blood signals doctors have to confirm or rule out that scenario, with specificity around 97 to 98 percent for ANCA-associated vasculitis.
Research on stored blood samples shows this antibody can appear in your bloodstream years before any symptoms surface, with a mean lead time of about 3.73 years before diagnosis. Knowing your level matters because the diseases this marker tracks can damage kidneys and lungs quickly once they declare themselves, and treatment timing affects organ outcomes.
PR3 antibody, also called PR3-ANCA (anti-neutrophil cytoplasmic antibody to proteinase 3), is an autoantibody of the IgG class. Its target, proteinase 3, is an enzyme stored inside neutrophils, a type of white blood cell that normally helps fight infection. When your immune system makes antibodies against PR3, those antibodies can stick to neutrophils and trigger them to attack the lining of small blood vessels.
This is the mechanism behind ANCA-associated vasculitis (AAV), a group of autoimmune diseases that includes granulomatosis with polyangiitis (GPA, formerly called Wegener's), microscopic polyangiitis, and a subset of eosinophilic granulomatosis with polyangiitis. PR3 antibody is most strongly tied to GPA, while a related antibody called MPO-ANCA is more often linked to microscopic polyangiitis.
PR3 antibody is the single most specific blood test for granulomatosis with polyangiitis. In a meta-analysis pooling diagnostic performance, the test correctly identified about 74 out of every 100 GPA cases, while correctly clearing about 97 out of every 100 people who did not have the disease. Modern PR3 immunoassays in AAV populations show pooled sensitivity around 80 to 87 percent and specificity around 97 to 98 percent.
Higher titers carry more diagnostic weight. A study of 288 people with suspected small-vessel vasculitis found that titers at or above 65 U/mL made true ANCA-associated vasculitis far more likely than mimicking conditions, and helped distinguish real disease from look-alikes such as infections and other autoimmune disorders.
PR3-positive disease tends to be more relapse-prone than MPO-positive disease, while MPO-positive kidney involvement carries worse renal outcomes. After treatment, persistently positive or rising PR3 antibody is associated with higher relapse risk, especially in people with kidney involvement, lung bleeding, or those treated with rituximab. Sustained negativity after rituximab is one of the strongest signals that remission will hold.
PR3 antibody is not only a vasculitis marker. In a study of 173 newly diagnosed ulcerative colitis patients, higher PR3-ANCA titers tracked with more extensive and severe colon inflammation and a greater need for steroids or advanced therapy. A pediatric study of 367 children found PR3-ANCA was a more accurate marker for ulcerative colitis than the related MPO-ANCA, with diagnostic accuracy curves around 0.79 to 0.87.
If you have unexplained chronic diarrhea, blood in your stool, or a family history of inflammatory bowel disease, a positive PR3 antibody points toward ulcerative colitis rather than Crohn's disease and can help estimate how aggressive the disease is likely to be.
In a 516-person study of people with primary sclerosing cholangitis (PSC, a chronic disease of the bile ducts), PR3 antibody combined with anti-glycoprotein 2 IgA identified those at higher risk of severe disease, poor survival, and bile duct cancer. The marker functions less as a diagnostic tool here and more as a prognostic flag in people already known to have the condition.
Because PR3 antibody assays vary by manufacturer and lab, exact cutpoints differ. The interpretive thresholds below come from a multicenter European study of 1,175 samples and a 288-person diagnostic study using common immunoassay platforms. They are orientation, not absolute targets. Your lab will report its own reference range and units.
| Tier | Range | What It Suggests |
|---|---|---|
| Negative | Below the lab's stated cutoff | AAV unlikely in the absence of strong clinical signs; rules the diagnosis out in many settings |
| Low positive | Above cutoff but below about 3 times the upper limit | Possible AAV; clinical context and repeat testing needed; false positives more common in this band |
| High positive | At or above 65 U/mL on common platforms, or roughly 3 times the upper limit | Strongly suggests ANCA-associated vasculitis; in one study, odds of true AAV versus mimickers were about 34 times higher in this range |
Source: Bossuyt et al. 2017 multicenter study; Mérindol et al. 2023 case-control study. Compare your results within the same lab and assay over time, since results from different platforms cannot be directly compared.
A single PR3 antibody result is most useful for diagnosis. Once you know your baseline, the trajectory matters more than any one number. In a 93-person study of ANCA-associated vasculitis, a decrease in PR3-ANCA at 2 to 4 months on treatment predicted later remission, and rising levels during remission predicted relapse, particularly with kidney or lung involvement.
If you are healthy and PR3-ANCA was checked as part of an autoimmune workup, a single negative result in the right clinical context is usually reassuring. If you are positive but asymptomatic, retest within 3 to 6 months to confirm and watch for clinical signs. If you have established AAV, most specialists recommend serial testing every 3 to 6 months during active disease and at least annually in stable remission, alongside symptom checks, urine testing, and kidney function labs.
A positive PR3 antibody is not a diagnosis on its own. Pair it with these next steps:
Evidence-backed interventions that affect your PR3 ANCA level
Proteinase 3 Antibody is best interpreted alongside these tests.